TATAA Biocenter to Distribute Swift Biosciences NGS Products in Europe
News Mar 10, 2016
Swift Biosciences has announced their partnership with TATAA Biocenter. This strategic partnership will expand both Swift’s and TATAA’s presence in Europe through TATAA Biocenter’s distribution and support of Swift’s NGS products in Sweden, Denmark, Norway, Germany, Austria, Slovakia, and the Czech Republic.
TATAA will also incorporate Swift’s NGS products in their popular NGS training courses offered throughout the year in various European locations. Kristina Lind, Coordinator of TATAA Biocenter’s hands-on training program, stated, “We always seek collaboration with the best solution providers for our training courses and Swift Biociences are top of the class for NGS library preparations.”
Mikael Kubista, President of TATAA Biocenter, added, “Our customers request professional tools for the entire NGS workflow from sample preparation and quality control to library preparation, sequencing, and data analysis. With Swift´s library kits, we can help our customers obtain larger yields and greater sequence coverage from small volume samples like FFPE and liquid biopsies.”
Swift Biosciences will provide reagents and support to Tataa Biocenter for their educational course concerning NGS applications, as well as technical expertise for TATAA’s role as a partner of the Cancer_ID Consortium in Europe. Tataa Biocenter’s focus in the consortium is on microRNA and some analysis of circulating tumor cells (CTC’s).
This strategic partnership helps expand the utility of Swift Biosciences’ NGS sample products into key applications, such as liquid biopsy analysis, for European end-users. Timothy Harkins, President and CEO of Swift, stated, “We are pleased to be partnering with an elite organization like TATAA Biocenter to train end users on the value of our differentiated product lines.
Enabling researchers to gain valuable information from precious samples like CTC’s and cfDNA is at the core of our organization and working with TATAA will help deliver these valuable solutions to more individuals.”
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE